Hematological Malignancy clinical trials

Explore recruiting hematological malignancy clinical trials.

Recruiting hematological malignancy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hematological Malignancy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FORMAT Study : Use of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusion - evaluation by rotem viscoelastometry (pilot single-center study).

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

France, Germany, Spain, Poland, Italy, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies

Germany, Poland, Italy, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Italy, Germany, Greece, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients with Hematologic Malignancies Previously Enrolled in Studies with Tafasitamab.

Italy, Spain, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hematological Malignancy trials by city

Hematological Malignancy in Toronto Hematological Malignancy in Vancouver Hematological Malignancy in Montreal Hematological Malignancy in Calgary Hematological Malignancy in Edmonton Hematological Malignancy in Ottawa Hematological Malignancy in Winnipeg Hematological Malignancy in Quebec City Hematological Malignancy in Hamilton Hematological Malignancy in Kitchener Hematological Malignancy in London Hematological Malignancy in Halifax Hematological Malignancy in New York Hematological Malignancy in Los Angeles Hematological Malignancy in Chicago Hematological Malignancy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease